消化器疾患治療マニュアル　改訂2版

出版社： 金芳堂
著者：
発行日： 2013-04-01
分野： 臨床医学：内科  >  消化器一般
ISBN： 9784765315609
電子書籍版： 2013-04-01 （改訂第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,720 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,720 円(税込)

購入する

商品紹介

本書は，研修医，臨床医を対象に，EBMに基づいた疾患概念の構築と診断・治療の手引きとして，EBMを基礎に現時点において最善と考えられる最新の治療法を紹介し概説したマニュアル書である。範囲が広い消化器領域について，複雑な疾患の病態や病因については省略し，患者説明や診断，治療を進めるうえで必要な情報にポイントを絞って簡潔にまとめ，実際の臨床の現場ですぐに活用できることを主眼に置いた。

目次

  • 消化器疾患治療マニュアル　改訂2版

    ―目次―

    １．肝疾患
    1）急性肝炎
    2）劇症肝炎
    3）B型慢性肝炎
    4）C型慢性肝炎
    5）肝硬変
    6）肝良性腫瘍
    7）肝細胞癌
    8）転移性肝癌
    9）薬物性肝障害
    10）自己免疫性肝炎
    11）原発性胆汁性肝硬変
    12）原発性硬化性胆管炎
    13）ウイルソン病、ヘモクロマトーシス
    14）アルコール性肝障害
    15）非アルコール性脂肪性肝疾患，非アルコール性脂肪性肝炎
    16）肝嚢胞，肝膿瘍

    ２．胆道疾患
    1）胆嚢結石，胆嚢炎
    2）胆管結石，胆管炎
    3）胆嚢ポリープ
    4）胆嚢腺筋腫症
    5）胆嚢癌，胆管癌

    ３．膵疾患
    1）急性膵炎
    2）慢性膵炎
    3）膵癌
    4）膵嚢胞性疾患
    5）自己免疫性膵炎
    6）神経内分泌腫瘍

    ４．食道疾患
    1）胃食道逆流症，逆流性食道炎，Barrett食道
    2）食道・胃静脈瘤
    3）食道癌
    4）食道アカラシア

    ５．胃・十二指腸疾患
    1）胃炎
    2）胃潰瘍，十二指腸潰瘍
    3）胃ポリープ，胃腺腫
    4）胃粘膜下腫瘍
    5）胃癌（早期胃癌・進行胃癌）
    6）胃悪性リンパ腫，腸管悪性リンパ腫，MALToma
    7）機能性ディスペプシア

    ６．腸疾患
    1）小腸疾患
    2）クローン病
    3）潰瘍性大腸炎
    4）大腸ポリープ，消化管ポリポーシス、 早期大腸癌
    5）進行大腸癌
    6）過敏性腸症候群
    7）虚血性腸炎
    8）感染性腸炎
    9）腸閉塞
    10）大腸憩室炎，虫垂炎
    11）放射線性腸炎
    12）消化管神経内分泌腫瘍、カルチノイド

    附．症候
    1) 急性腹症
    2) 消化管出血
    3) 癌性疼痛

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 肝疾患

P.10 掲載の参考文献
1) 独立行政法人国立国際医療研究センター肝炎情報センターホームページ : (http://www.ncgm.go.jp/center/forpatient_ah.html)
 
2) Matsuura K, et al : Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol 47 : 1476-1483, 2009.
 
3) Orito E, et al : Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34 : 35-39, 2001.
 
4) Suzuki Y, et al : Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 76 : 33-39, 2005.
PubMed
5) Tei S, et al : Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 362 : 371-373, 2003.
PubMed
6) 日本超音波検査学会 : 腹部超音波テキスト, 第3版, 医歯薬出版株式会社, 2004.
 
7) Brok J, et al. Glucocorticosteroids for viral hepatitis C. Cochrane Database Syst Rev 2 : 2004
PubMed
8) Yu JW, et al. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci 55 : 775-783, 2010.
 
9) Tassopoulos NC, et al. Recombinant interferon-alpha therapy for acute hepatitis B : a randomized, double-blind, placebo-controlled trial. J Viral Hepat 4 : 387-394, 1997.
 
10) 小池和彦, 他 : HIV・HBV重複感染時の診療ガイドライン平成20年度厚生労働省化学研究費補助金エイズ対策研究事業「HIV感染症に合併する各種疾病に関する研究」班, 2009.
 
11) Poynard T, et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev 1 : 2002
PubMed
12) Kamal SM, et al. Peginterferon alfa-2b therapy in acute hepatitis C : impact of onset of therapy on sustained virologic response. Gastroenterology 130 : 632-638, 2006.
 
13) 大阪大学病院感染制御部 : 感染管理マニュアル. 2012.
 
P.24 掲載の参考文献
1) Gimson AES, et al : Late onset hepatic failure. Clinical, serological and histological findings. Hepatology 6 : 288-294, 1986.
 
2) 坪内博仁, 他 : 劇症肝炎及び遅発性肝不全 (LOHF : late onset hepatic failure)の全国集計 (2009年) 厚生労働省科学研究費補助金 (難治性疾患克服研究事業) 「難治性の肝・胆道疾患に関する調査研究」平成22年度総括・分担研究報告書 : 96-113, 2011.
 
3) Inoue K, et al : Clinical and molecular virological differences between fulminant hepatic failures following acute and chronic infection with hepatitis B virus. J Med Virol 55 : 35-41, 1998.
PubMed
4) Perkins JD : Another formula to determine the prognosis of patients with acute liver failure. Liver Transpl 15 : 986-91, 2009.
PubMed
5) 持田智 : 劇症肝炎 : わが国における問題点 肝臓 50 : 497-506, 2009.
 
6) 川崎誠治 : 脳死肝移植の現状と展望 日本消化器病学会雑誌 108 : 717-722, 2011.
Medical*Online
7) Yoshiba M, et al : Accurate prediction of fulminant hepatic failure in severe acute viral hepatitis : multicenter study. J Gastroenterol 37 : 916-921, 2002.
PubMed
8) 持田智, 他 : (1) 劇症肝炎の診断基準 : プロトロンビン時間の扱いに関する検討, (2) 劇症肝炎, 急性肝不全の概念の改変, (3) 肝移植ガイドラインの改訂. 「厚生労働省科学研究費補助金 (難治性疾患克服研究事業) 「難治性の肝・胆道疾患に関する調査研究班」平成20年度報告書」 16-18, 2009.
 
9) Lok AS, et al : Reactivation of hepatitis B virus replication in patients receiving cytotoxic chemotherapy. Report of a prospective study. Gastroenterology 100 : 182-188, 1991.
PubMed
10) Michalak TI, et al : Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 93 : 230-239, 1994.
PubMed
11) Kawatani T, et al : Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 67 : 45-50, 2001.
PubMed
12) 清澤研道, 他 : 免疫抑制・化学療法中に発生するde novo B型急性肝炎の発症機序の検討. 「厚生労働省肝炎等克服緊急対策事業「B型及びC型肝炎ウイルスの感染者に対する治療の標準化に関する臨床的研究」班平成18年度研究報告書」 30-32, 2007.
 
13) 坪内博仁, 他 : 免疫抑制・化学療法により発症するB型肝炎対策-厚生労働省「難治性の肝・胆道疾患に関する調査研究」班 劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告- 肝臓 50 : 38-42, 2009.
 
14) Urata Y, et al : Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 21 : 16-23, 2011.
PubMed
P.40 掲載の参考文献
1) Suzuki F, et al : Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 81 : 27-33, 2009.
PubMed
2) Orito E, et al : Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34 : 590-594, 2001.
PubMed
3) Chisari FV : Cytotoxic T cells and viral hepatitis. J Clin Invest 99 : 1472-1477, 1997.
PubMed
4) Friedrich-Rust M, et al : Liver fibrosis in viral hepatitis : noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 252 : 595-604, 2009.
PubMed
5) 坪内博, 他 : 免疫抑制・化学療法により発症するB型肝炎対策 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告. 肝臓 50 : 38-42, 2009.
 
6) Chen CJ, et al : Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 295 : 65-73, 2006.
PubMed
7) Kumada T, et al : Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values. J Med Virol 82 : 539-545, 2010.
PubMed
8) 林紀夫, 他 : B型慢性肝炎患者に対するペグインターフェロンα-2aの有効性及び安全性の検討. 肝臓 53 : 135-146, 2012.
 
9) Cooksley WG, et al : Peginterferon alpha-2a (40 kDa) : an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10 : 298-305, 2003.
PubMed
10) Lai CL, et al : A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.N Engl J Med 339 : 61-68, 1998.
 
11) Lai CL, et al : Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36 : 687-696, 2003.
PubMed
12) Marcellin P, et al : Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 : 808-816, 2003.
PubMed
13) Hadziyannis SJ, et al : Adefovir dipivoxil for the treatment of hepatitis B e antigennegative chronic hepatitis B. N Engl J Med 348 : 800-807, 2003.
PubMed
14) Chang TT, et al : A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 : 1001-1010, 2006.
 
15) Yokosuka O, et al : Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol 52 : 791-799, 2010.
PubMed
16) Tenney DJ, et al : Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49 : 1503-1514, 2009.
PubMed
17) 田中榮司, 他 : 核酸アナログ薬中止に伴うリスク回避のための指針2012 厚生労働省「B型肝炎の核酸アナログ薬治療における治療中止基準の作成と治療中止を目指したインターフェロン治療の有用性に関する研究」の報告. 肝臓 53 : 237-242, 2012.
 
18) Heathcote EJ, et al : Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140 : 132-143, 2011.
PubMed
19) Han SH, et al : Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 9 : 182-187, 2003.
PubMed
P.58 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドライン作成委員会 : C型肝炎治療ガイドライン, 第1版, 2012.
 
2) Kumada H, et al : Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 56 : 78-84, 2012.
PubMed
3) Hayashi N, et al : Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-totreat patients with genotype 1 chronic hepatitis C. J Viral Hepat 19 : e134-e142, 2012.
 
4) McHutchison JG, et al : Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123 : 1061-1069, 2012.
 
5) Oze T, et al : Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. J Viral Hepat 16 : 578-585, 2009.
PubMed
6) Hiramatsu N, et al : Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat 16 : 586-594, 2009.
PubMed
7) Berg T, et al : Extended treatment duration for hepatitis C virus type 1 : comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130 : 1086-1097, 2006.
PubMed
8) Oze T, et al : The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. J Gastroenterol 46 : 944-952, 2011.
PubMed
9) Oze T, et al : Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. J Hepatol 54 : 604-611, 2011.
PubMed
10) Sherman KE, et al : Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365 : 1014-1024, 2011.
PubMed
11) Zeuzem S, et al : Telaprevir for retreatment of HCV infection. N Engl J Med 364 : 2417-2428, 2011.
PubMed
12) 林紀夫 : Primary analysis of TMC4335 plus PEGIFN/RBV in treatment-naive patients infected with HCV genotype 1 (DRAGON study). JDDW 2011.
 
13) Zeuzem S, et al : TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ribavirin treatment : Final SVR24 results of the ASPIRE trial. J Hepatol 56 : S1, 2012.
 
14) Chayama K, et al : Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55 : 742-748, 2012.
PubMed
P.73 掲載の参考文献
1) 青柳豊, 他 : 本邦の肝硬変の成因と現状 : 第44回日本肝臓学会総会主題ポスター「肝硬変の成因別実態」のまとめ. 肝硬変の成因別実態 2008. 東京, 中外医学社, 1-10, 2008.
 
2) Villeneuve JP, et al : Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 31 : 207-210, 2000.
PubMed
3) B型C型慢性肝炎・肝硬変のガイドライン (平成23年度厚生労働省厚生科学研究費肝炎等克服緊急対策研究事業 (肝炎分野) ウイルス性肝炎における最新の治療法の標準化を目指す研究班)
 
4) Liaw YF, et al : Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engle J Med 351 : 1521-1531, 2004.
 
5) 泉並木, 他 : C型肝炎症例におけるPEG-IFNα2a 少量長期投与による肝発癌抑止効果の検討全国多施設共同研究. 肝臓 52 : A493, 2011.
 
6) 日本肝臓学会 : C型肝炎治療ガイドライン, 第1版, 2012.
 
7) Tsuchiya M, et al : The effect of a late evening snack in patients with liver cirrhosis. Hepatol Res 6 : 95-103, 2005.
 
8) Sato S, et al : Clinical comparison of branched-chain amino acid (I-Leucine, I-Isoleucine, I-Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV-EN study). Hepatol Res 21 : 232-240, 2005.
 
9) Muto Y, et al : Effect of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 3 : 705-713, 2005.
PubMed
10) Nakaya Y, et al : BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition 23 : 113-120, 2007.
PubMed
11) Schirier RW, et al : Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355 : 2099-2112, 2006.
 
12) Romanelli RG, et al : Long-term albumin infusion improves survival in patients with cirrhosis and ascites : an unblinded randomized trial. World J Gastroenterol 12 : 1403-1407, 2006.
PubMed
13) Moore KP, et al : The management of ascites in cirrhosis : report on the consensus conference of International Ascites Club. Hepatology 38 : 258-266, 2003.
PubMed
14) Plauth M, et al : ESPEN guideline for nutrition in liver disease and transplantation. Clin Nutr 16 : 43-55, 1997.
 
15) A. S. P. E. N. Board of Directors and the Clinical Guideline Task Force : Guideline for the use of parenteral and enteral nutrition in adult and pediatric patients. Liver disease. JPEN 26 : 65SA-68SA, 2002.
 
16) Yoshida Y, et al : Effects of zinc deficiency/Zinc supplementation on ammonia metabolism in patients with decompensated liver cirrhosis. Acta Med Okayama 55 : 349-355, 2001.
PubMed
17) 市田隆文, 他 : 非代償性肝硬変に対する生体肝移植の適応と治療成績. 肝胆膵 50 : 791-795, 2005.
Medical*Online
P.79 掲載の参考文献
1) Bo Yoon Choi, et al : The Diagnosis and Management of Benign Hepatic Tumors. J Clin Gastroenterol 39 : 401-412, 2005.
PubMed
2) Bahirwani R, et al : Review article : the evaluation of solitary liver masses. Aliment Pharmacol Ther 15 : 953-965, 2008.
 
3) Gandolfi L, et al : Natural history of heptic haemangiomas : clinical and ultrasound study. Gut 32 : 677-680, 1991.
 
4) Buell JF, et al : Management of Benign Hepatic tumors. Surg Clin N Am 90 : 719-735, 2010.
PubMed
5) International Working Party : Terminolgy of nodular hepatocellular lesions. Hepatology 22 : 983-993, 1995.
 
6) Wanless IR, et al : On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology 5 : 1194-1200, 1985.
PubMed
7) Fukukura Y, et al : Angioarchitecture and blood circulation in focal nodular hyperplasia of the liver. J Hepatol 29 : 470-475, 1998.
 
8) Rooks JB, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 242 : 644-648, 1979.
PubMed
9) Soe KL, et al : Liver pathology associated with the use of anabolic-andorogenic steroids. Liver 12 : 73-79, 1992.
 
10) Labrune P, et al : Hepatocellular adenomas in glycogen storage disease type I and III : a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 24 : 276-279, 1997.
 
11) Talente GM, et al : Glycogen storage disease in adults. Ann Intern Med 120 : 218- 226, 1994.
 
12) Reddy KR, et al : Benign and solid tumors of the liver : relationship to sex, age, size of tumors, and outcome. Am Surg 67 : 173-178, 2001.
PubMed
13) Stoot JH, et al : Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas : a systematic review including more than 1600 adenomas cases. HPB (Oxford) 12 : 509-522, 2010.
PubMed
14) van Aalten SM, et al : Systematic review of hemorrhage and rupture of hepatocellular adenomas. Br J Surg 99 : 911-916, 2012.
PubMed
15) Dokmak S, et al : A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 137 : 1698-1705, 2009.
PubMed
P.91 掲載の参考文献
1) Fattovich G, et al : Hepatocellular carcinoma in cirrhosis : incidence and risk factors. Gastroenterology 127 : S35-S50, 2004.
PubMed
2) Matsuda T, et al : Cancer incidence and incidence rates in Japan in 2006 : based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 42 : 139-147, 2012.
PubMed
3) Ikai I, et al : Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res 40 : 1043-1059, 2010.
PubMed
4) Tateishi R, et al : Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 103 : 1201-1209, 2005.
PubMed
5) Yoshida H, et al : Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group.Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 : 174-181, 1999.
 
6) Chen CJ, et al : Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 : 65-73, 2006.
PubMed
7) El-Serag HB, et al : Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126 : 460-468, 2004.
PubMed
8) Jung EM, et al : Vascularization of liver tumors - preliminary results with Coded Harmonic Angio (CHA), phase inversion imaging, 3D power Doppler and contrast mediumenhanced B-flow with second generation contrast agent (Optison). Clin Hemorheol Microcirc 34 : 483-497, 2006.
PubMed
9) Bruix J, et al : Management of hepatocellular carcinoma : an update. Hepatology 53 : 1020-1022, 2011.
PubMed
10) Imai Y, et al : Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma : correlation with histological grading. Hepatology 32 : 205-212, 2000.
PubMed
11) Hayashi M, et al : Progression to hypervascular hepatocellular carcinoma : correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 225 : 143-149, 2002.
PubMed
12) Okazumi S, et al : Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET : characterization of tumor and assessment of effect of treatment. J Nucl Med 33 : 333-339, 1992.
PubMed
13) Torizuka T, et al : In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36 : 1811-1817, 1995.
 
14) Nishiguchi S, et al : Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346 : 1051-1055, 1995.
PubMed
15) Arase Y, et al : The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79 : 1494-1500, 1997.
 
16) Shiina S, et al : A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129 : 122-130, 2005.
PubMed
17) Ishii H, et al : Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 77 : 1792-1796, 1996.
PubMed
18) Camma C, et al : Transarterial chemoembolization for unresectable hepatocellular carcinoma : meta-analysis of randomized controlled trials. Radiology 224 : 47-54, 2002.
PubMed
19) Mazzaferro V, et al : Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 : 693-699, 1996.
PubMed
20) Todo S, et al ; Japanese Study Group on Organ Transplantation : Living donor liver transplantation for adult patients with hepatocellular carcinoma : experience in Japan. Ann Surg 240 : 451-459, 2004.
 
21) Sakon M, et al : Combined intraarterial 5-fluorouracil and subcutaneous interferonalpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94 : 435-442, 2002.
PubMed
22) Chung YH, et al : Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 1 ; 88 : 1986-1991, 2000.
 
23) Llovet JM, et al : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 : 378-390, 2008.
PubMed
24) Ikeda K, et al : Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32 : 228-232, 2000.
PubMed
P.97 掲載の参考文献
1) Nasu K, et al : Hepatic metastases : diffusion-weighted sensitivity-encoding versus SPIOenhanced MR imaging. Radiology 239 : 122-130. 2006.
PubMed
2) Huppertz A, et al : Improved detection of focal liver lesions at MR imaging : multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 230 : 266-275. 2004.
PubMed
3) 大腸癌研究会 : 大腸癌治療ガイドライン, 医師用, 2010年版, 金原出版, 東京, 2010.
 
4) Pawlik TM, et al : Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 11 : 1057-1077, 2007.
 
5) Kato T, et al : Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy. Dis Colon Rectum 46 : S22-S31, 2003.
PubMed
6) Rodgers MS et al : Surgery for colorectal liver metastasis with hepatic lymphnode involvement : a systematic review. Br J Surg 87 : 1142-1155, 2000.
 
7) Saiura A, et al : Clinicopathological features and outcome ofhepatic resection for liver metastasis from gastric cancer. Hepatogastroenterology 49 : 1062-1065, 2002.
 
8) Okano K, et al : Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 235 : 86-91, 2002.
PubMed
9) Frilling A, et al : Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 12 : 361-379, 2010.
PubMed
10) Mocellin S, et al : Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer : the end of an era? J Clin Oncol 25 : 5649-5654, 2007.
PubMed
11) Arai Y, et al : Management of patients with unresectable liver metastases from colorectal and gastric cancer employing an implantable port system. Cancer Chemother Pharmacol 31 : S99-S102, 1992.
PubMed
12) 椎名秀一朗, 他 : 【転移性肝癌 多様化する治療】 転移性肝癌に対する経皮的ラジオ波焼灼術. 10年間の成績と今後の展望 (解説/特集). 臨床消化器内科 26 : 405-413, 2011.
 
P.109 掲載の参考文献
1) 多賀須幸男, 他 : 今日の消化器疾患治療指針, 第2版, 医学書院, 2002.
 
2) 高瀬幸次郎, 他 : 薬剤性劇症肝炎の特徴. 肝胆膵 48 : 731-738, 2004.
Medical*Online
3) Takikawa H, et al : Drug-induced liver injury in Japan : An analysis of 1676 cases between 1997 and 2006. Hepatol Res 39 : 427-431, 2009.
PubMed
4) 石田聡 : 健康食品による薬物性肝障害. 肝胆膵 48 : 747-755, 2004.
Medical*Online
5) 佐田通夫, 他 : 痩せ薬・健康食品による薬物性肝障害2次全国調査集計結果 (日本肝臓学会主催), 肝臓 45 : 96-108, 2004.
 
6) 岩佐元雄, 他 : 薬物代謝の視点からみた薬物性肝障害の病態. 肝胆膵 48 : 677-681, 2004.
Medical*Online
7) 高橋芳樹, 他 : 肝臓 42 : 288-296, 2001.
 
8) 滝川一 : 薬物性肝障害の本邦の診断基準 (1978) と問題点. 肝胆膵 48 : 699-702, 2004.
Medical*Online
9) 滝川一, 他 : DDW-J 2004ワークショップ薬物性肝障害診断基準の提案. 肝臓 46 : 85-90, 2005.
 
10) 松崎靖司, 他 : 薬物性肝障害の治療の実際. 肝胆膵 48 : 777-783, 2004.
Medical*Online
11) 松崎靖司, 他 : 薬物性肝障害の治療 : 治療の実際とEBMに基づくUDCAの効果. 日消誌 100 : 659-666, 2003.
Medical*Online
P.121 掲載の参考文献
1) 戸田剛太郎 : 自己免疫性肝炎診断指針 1996. 肝臓 37 : 298-300, 1996.
 
2) Stravitz RT, et al : Autoimmune acute liver failure : proposed clinical and histological criteria. Hepatology 53 : 517-526, 2011.
PubMed
3) Abe M, et al : Present status of autoimmune hepatitis in Japan : a nationwide survey. J Gastroenterol 46 : 1136-1141, 2011.
PubMed
4) Alvarez F, et al : International Autoimmune Hepatitis Group Report : review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 : 929-938, 1999.
PubMed
5) Hennes EM, et al : Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48 : 169-176, 2008.
PubMed
6) 戸田剛太郎 : 自己免疫性肝炎・消化器病診療-よきインフォームドコンセントにむけて. 169-173, 医学書院, 2004.
 
7) Manns MP, et al : Diagnosis and management of autoimmune hepatitis. Hepatology 51 : 2193-2213, 2010.
PubMed
8) Toda G, et al : Present status of autoimmune hepatitis in Japan-correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis. J Hepatol 26 : 1207-1212, 1997.
 
9) Miyake Y, et al : Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. Hepatol Int 3 : 556-562, 2009.
PubMed
10) 持田智 : 厚生労働省科学研究費補助金難治性疾患克服研究事業「難治性の肝・胆道疾患に関する調査研究 平成19年度総括・分担研究報告書」, 110-113, 2008.
 
11) Soen S, et al : Glucocorticoid-induced osteoporosis : skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. Mod Rheumatol 15 : 163-168, 2005.
PubMed
12) Duclos-Vallee JC, et al : Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Livr Trnspl 15 (Suppl 4) : S25-S34, 2009.
 
13) 布井弘明, 他 : HBV持続感染に対してラミブジンを併用してステロイド治療を施行した自己免疫性肝炎の1例. 肝臓 46 : 557-562, 2005.
 
14) Chazouilleres O, et al : Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome : clinical features and response to therapy. Hepatology 28 : 296-301, 1998.
PubMed
P.132 掲載の参考文献
1) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班 : 原発性胆汁性肝硬変 (PBC)の診療ガイドライン, 2012.
 
2) Nakamura M, et al : Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45 : 118-127, 2007.
PubMed
3) Scheuer P, et al : Primary biliary cirrhosis. Proc R Soc Med 60 : 1257-1260, 1967.
PubMed
4) Ludwig J, et al : Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch Pathol Anat 379 : 103-112, 1978.
PubMed
5) 中沼安二, 他 : PBCの新しい病期・活動度分類の提案. 日消誌 108 : 1817-1822, 2011.
Medical*Online
6) Poupon RE, et al : A multicenter, controlled trial of urosodiol for the treatment of primary biliary cirrhosis. UDCA-PBC study Group.N Engl J Med 324 : 1548-1554, 1991.
 
7) Lindor KD, et al : American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology 50 : 291-308, 2009.
 
8) European Association for the Study of the Liver. EASL Clinical Practice Guidelines. Management of cholestatic liver diseases. J Hepatol 51 : 237-267, 2009.
 
9) Pares A, et al : Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 130 : 715-720, 2006.
PubMed
10) Shi J, et al : Long-term effects of mild-dose ursodeoxycholic acid in primary biliary cirrhosis : a meta-analysis of randomized controlled trials. Am J Gastroenterol 101 : 1529-1538, 2006.
 
11) Iwasaki S, et al : The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis : A prospective, multicenter study. Hepatol Res 38 : 557-564, 2008.
PubMed
12) Chazouilleres O, et al : Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 44 : 400-406, 2006.
PubMed
13) 日本肝移植研究会 : 肝移植症例登録報告. 移植 46 : 524-536, 2011.
Medical*Online
14) Montano-Loza AJ, et al : Cyclosporine A protects against primary biliary cirrhosis recurrence after liver transplantation. Am J Transplan 10 : 852-858, 2010.
 
15) Khurana S, et al : Rifampin is safe for the treatment of pruritus due to chronic cholestasis : a meta-analysis of prospective randomized-controlled trial. Liver Int 26 : 943-948, 2006.
PubMed
16) 骨粗鬆症の予防と治療ガイドライン作成委員会 : 骨粗鬆症の予防と治療ガイドライン2006年版, ライフサイエンス出版.
 
17) Tandon P, et al : The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 102 : 1528-1536, 2007.
PubMed
P.137 掲載の参考文献
1) Takikawa H, et al : Analysis of 388 cases of primary sclerosing cholangitis in Japan. Presence of a subgroup without pancreatic involvement in older patients. Hepatol Res 29 : 153-159, 2004.
PubMed
2) 中沢貴宏 , 他 : IgG4 関連硬化性胆管炎の診断と治療. 胆道 24 : 569-578, 2010.
Medical*Online
3) Nguyen D, et al : Primary sclerosing cholangitis. In Schiff E ed. Schiff's Disease of the Liver. Philadelphia : Wiley-Blackwell : 477-488, 2012.
 
4) 田中篤, 他 : PSCの診断基準. 胆と膵 33 : 469-473, 2012.
Medical*Online
5) Chapman R, et al : Diagnosis and management of primary sclerosing cholangitis. Hepatology 51 : 660-678, 2010.
PubMed
6) Dave M, et al : Primary sclerosing cholangitis : meta-analysis of diagnostic performance of MR cholangiopanceratography. Radiology 256 : 387-396, 2010.
PubMed
7) Gotthardt D, et al : Endoscopic retrograde cholangiopancreatography in diagnosis and treatment of primary sclerosing cholangitis. Clin Liver Dis 14 : 349-358, 2010.
PubMed
8) Wiesner RH, et al : Primary sclerosing cholangitis : natural history, prognostic factors and survival analysis. Hepatology 10 : 430-436, 1989.
PubMed
9) Farrant JM, et al : Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 100 : 1710-1717, 1991.
PubMed
10) Broome U, et al : Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38 : 610-615, 1996.
PubMed
11) Tischendorf JJ, et al : Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis : A single center study. Am J Gastroenterol 102 : 107-114, 2007.
PubMed
12) Poropat G, et al : Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev CD003626, 2011.
PubMed
13) Shi J, et al : Ursodeoxycholic acid in primary sclerosing cholangitis : meta-analysis of randomized controlled trials. Hepatol Res 39 : 865-873, 2009.
PubMed
14) Triantos CK, et al : Meta-analysis : ursodeozycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther 34 : 901-910, 2011.
PubMed
15) EASL Clinical Practice Guidelines : management of cholestatic liver disease. J Hepatol 51 : 237-267, 2009.
PubMed
16) Giljaca V, et al : Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst Rev CD004036, 2010.
PubMed
17) Gotthardt D, et al : Endoscopic retrograde cholangiopancreatography in diagnosis and treatment of primary sclerosing cholangitis. Clin Liver Dis 14 : 349-358, 2010.
PubMed
18) Gotthardt D, et al : Endoscopic dilation of dominant stenosis in primary sclerosing cholangitis : outcome after long-term treatment. Gastrointest Endosc 71 : 527-534, 2010.
PubMed
19) 日本肝移植研究会 : 肝移植症例登録報告. 移植 46 : 524-536, 2012.
 
20) Mizuno S, et al : Bezafibrate for the treatment of primary sclerosing cholangitis. J Gastroenterol 45 : 758-762, 2010.
PubMed
21) MartinCR, et al : The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther 35 : 255-265, 2012.
PubMed
P.144 掲載の参考文献
1) Bull PC, et al : The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 5 : 327-337, 1993.
 
2) Adams PC, et al : Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 352 : 1769-1778, 2005.
 
3) 高後裕 : 日本内科学会雑誌 100 : 2412-2424, 2011.
 
4) Jezequel P, et al : Allele frequencies of hereditary hemochromatosis gene mutations in a local population of west Brittany. Hum Genet 102 : 332-333, 1998.
 
5) Ryan E, et al. Hemochromatosis in Ireland and HFE. Blood Cells Mol Dis 24 : 428-432, 1998.
PubMed
6) 日本肝移植研究会 : 肝移植症例登録報告. 移植 46 : 524-536, 2011.
Medical*Online
7) 輸血後鉄過剰症の診療ガイド : 厚生労働科学研究費補助金難治性疾患克服研究事業特発性造血障害に関する調査研究 (平成20年度).
 
8) Maggio A, et al : Improving survival with deferiprone treatment in patients with thalassemia major : a prospective multicenter randomized clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis 42 : 247-251, 2009.
PubMed
P.153 掲載の参考文献
1) 厚生統計協会 : 厚生の指標「国民衛生の動向」, 92, 2000.
 
2) 日本肝癌研究会追跡調査委員会, 第18回全国原発性肝癌追跡調査報告 (2004-2005). 肝臓 51 : 460-484, 2010.
 
3) 文部省科学研究費補助金総合 (A) 「アルコール性肝硬変・肝癌の成因と病態に関する総合的 (疫学から分子生物学まで) 研究」 (高田班. 1991年).
 
4) アルコール医学生物学研究会 : JASBRAアルコール性肝障害診断基準 (2011年版) , 旭川, 2012.
 
5) 堀江義則, 他 : 重症型アルコール性肝炎の全国調査. 日本消化器病学会誌 99 : 1326-1333, 2002.
 
6) 堤幹宏, 他 : 重症アルコール肝炎の治療. 肝臓 43 : 305-308, 2002.
 
7) 石井邦英, 他 : 早期にMOFを呈した重症型アルコール性肝炎の2救命例. 日本救命医療研究会誌 9 : 147-154, 1995.
 
8) 森朱夏, 他 : 白血球除去療法を施行し救命しえた若年女性の重症型アルコール性肝炎の1例. アルコールと医学生物学 24 : 114-119, 2004.
 
9) Belle SH, et al : Liver transplantation for alcoholic liver disease in the United States : 1988 to 1995. Liver Transpl Surg 3 : 212-219, 1997.
PubMed
10) Hoofnagle JH, et al : Liver transplantation for alcoholic liver disease. Liver Transpl Surg 3 : 347-350, 1997.
PubMed
11) Sherlock S. & Dooley J. Diseases of the liver and biliary system, 11th edition : 381-398, Blackwell Science.
 
12) Imperiale TF, et al : Do corticosteroids reduce mortality from alcoholic hepatitis? Ann Intern Med 113 : 299-307, 1990.
PubMed
13) Ramond M, et al : A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 326 : 507-512, 1992.
PubMed
14) Rambaldi A, et al : Systematic review : glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 27 : 1167-1178, 2008.
PubMed
15) Yin M, et al : Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 117 : 942-952, 1999.
PubMed
16) Tilg H, et al : Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 38 : 419-425, 2003.
PubMed
17) Menon KV et al : A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 99 : 255-260, 2004.
PubMed
18) Boetticher NC, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 135 : 1953-1960, 2008.
PubMed
19) Akriviadis E, et al : Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis : a double-blind, placebo-controlled trial. Gastroenterology 119 : 1637-1648, 2000.
PubMed
20) Jalan R, et al : Extracorporeal liver support with molecular absorbents recirculating system in patients with severe alcoholic hepatitis. J Hepatol 38 : 24-31, 2003.
 
21) Cabre E, et al : Short-and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition : a multicenter randomized trial. Hepatology 32 : 36-42, 2000.
PubMed
22) Tomita K, et al : Pioglitazone prevents alcohol-induced fatty liver in rats through upregulation of c-Met. Gastroenterology 126 : 873-885, 2004.
PubMed
23) You M, et al : Role of adiponectin in the protecrive action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 42 : 568-577, 2005.
PubMed
P.168 掲載の参考文献
1) 日本肝臓学会 : NASH・NAFLDの診療ガイド2010, 文光堂, 2010.
 
2) 岡上武, 他 : 日本肝臓学会コンセンサス神戸 2009 : NASHの診断と治療. 肝臓 50 : 741-747, 2009.
 
3) メタボリックシンドローム診断基準検討委員会 : メタボリックシンドロームの定義と診断基準. 日内会誌 94 : 794-809, 2005.
 
4) Angulo P : Nonalcoholic fatty liver disease. N Engl J Med 346 : 1221-1231, 2002.
PubMed
5) Kamada Y, et al : Adipocytokines and liver disease. J Gastroenterol 43 : 811-822, 2008.
PubMed
6) Romes S, et al : Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40 : 1461-1465, 2008.
 
7) Kawaguchi T, et al : Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 7 : e38322, 2012.
PubMed
8) Yatsuji S, et al : Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 24 : 248-254, 2009.
PubMed
9) Yasui K, et al : Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 9 : 428-433, 2011.
PubMed
10) Sumida Y, et al : A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatisis in nonalcoholic fatty liver disease. J Gastroenterol 46 : 257-268, 2010.
 
11) Yoneda M, et al : Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol 46 : 1300-1306, 2011.
PubMed
12) Sullivan S, et al : Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology 55 : 1738-1745, 2012.
PubMed
13) 肥満症治療ガイドライン作成委員会 : 肥満症治療ガイドライン2006. 肥満研究 12 : 臨時増刊号増刷改訂版, 2006.
 
14) Sanyal AJ, et al : Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362 : 1675-1685, 2010.
 
15) Bugianesi E, et al : A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100 : 1082-1090, 2005.
PubMed
16) Nelson A, et al : A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis : a randomized placebo-controlled trial. J Clin Gastroenterol 43 : 990-994, 2009.
 
17) Merat S, et al : Probucol in the treatment of non-alcoholic steatohepatitits : a doubleblind randomized controlled study. J Hepatol 38 : 414-418, 2003.
 
18) Chan DC, et al : Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 33 : 1134-1139, 2010.
PubMed
19) Georgescu EF, et al : Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 15 : 942-954, 2009.
PubMed
20) Morita Y, et al : Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Heaptogastroenterology 52 : 1338-1343, 2005.
 
21) Kenny PR, et al : Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis : A case series. Am J Gastroenterol 105 : 2707-2709, 2010.
PubMed
22) Yilmaz Y, et al : Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belq 75 : 240-244, 2012.
PubMed
23) Mummadi RR, et al : Effect of bariatric surgery on non-alcoholic fatty liver disease (NAFLD) : systematic review and meta-analysis. Clin Gastroenterol Hepatol 6 : 1396-1402, 2008.
 
24) Patil DT, et al : The evolution of nonalcoholic fatty liver disease recurrence post liver transplantation. Liver Transpl 18 : 1147-1153, 2012.
 
P.175 掲載の参考文献
1) Cowles RA, et al : Solitary hepatic cysts. J Am Coll Surg 191 : 311-321, 2000.
PubMed
2) Arie Regev, et al : Diagnosis and management of cystic lesions of the liver. In : UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2010.
 
3) Yoshida H, et al : Long-term results of multiple minocycline hydrochloride injections for the treatment of symptomatic solitary hepatic cyst. J Gastroenterol Hepatol 18 : 595-598, 2003.
PubMed
4) Zerem E, et al : Percutaneous treatment of symptomatic non-parasitic benign liver cysts : single-session alcohol sclerotherapy versus prolonged catheter drainage with negative pressure. Eur Radiol 18 : 400-406, 2008.
PubMed
5) 荒川泰行, 他 : 肝膿瘍, 肝寄生虫. 綜合臨牀 56 増刊 : 1210-1215, 2007.
Medical*Online
6) Joshua Davis, et al : Pyogenic liver abscess. In : UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2011.
 
7) 山上裕晃, 他 : 肝膿瘍. 綜合臨牀 57 増刊 : 1048-1049, 2008.
Medical*Online
8) Yu SC, et al : Treatment of pyogenic liver abscess : prospective randomized comparison of catheter drainage and needle aspiration. Hepatology 39 : 932, 2004.
PubMed
9) Zerem E, et al : Sonographically guided percutaneous catheter drainage versus needle aspiration in the management of pyogenic liver abscess. AJR Am J Roentgenol 189 : W138, 2007.
PubMed
10) Tan YM, et al : An appraisal of surgical and percutaneous drainage for pyogenic liver abscesses larger than 5cm. Ann Surg 241 : 485, 2005.
 
11) Bertel CK, et al : Treatment of pyogenic hepatic abscesses : Surgical vs percutaneous drainage. Arch Surg 121 : 554, 1986.
PubMed
12) Chen YW, et al : A pilot study of oral fleroxacin once daily compared with conventional therapy in patients with pyogenic liver abscess. J Microbiol Immunol Infect 35 : 179, 2002.
PubMed

2章 胆道疾患

P.185 掲載の参考文献
1) 厚生統計協会 : 患者調査に基づく推計患者数, 傷病小分類・年次別・厚生の指標 39 : 29-35, 1993.
 
2) 和田浩一, 他 : 無症状胆石の自然経過. 日本臨牀 7 : 1737-1743, 1993.
Medical*Online
3) 阿部朝美, 他 : 無症状胆石の自然史に基づく治療法の選択. 胆と膵 4 : 287-291, 1998.
Medical*Online
4) Kratzer W, et al : Risk factors and natural history of gallstone disease. : The Proceeding of Falk Symposium No. 139, Freiburg Germany, January 15-16, 2004.
 
5) Okamoto M, et al : The relationship between gallbladder disease and smoking and drinking habits in middle-aged Japanese. J Gastroenterol 37 : 455-462, 2002.
PubMed
6) Kono S, et al : Cigarette smoking, alcohol use, and gallstone risk in Japanese men. Digestion 65 : 177-118, 2002.
PubMed
7) Friedman G, et al : Prognosis of gallstones with mild or no symptoms : 25 years of followup in a health maintenance organization. J Clin Epidemiol 42 : 127-136, 1989.
 
8) 中程純, 他 : 慢性胆嚢炎. 日本臨牀別冊 肝・胆道系症候群III. 第2版, p.238-241, 日本臨牀, 2011.
 
9) Wskelinen M, et al : Diagnostic approaches in acute cholecystitis ; a prospective study of 1333 patients with acute abdominal pain. Theor Surg 8 : 15-20, 1993.
 
10) Trowbridge RL, et al : Does this patient have acute cholecystitis? JAMA 289 : 80-86, 2003.
PubMed
11) 急性胆道炎の診療ガイドライン作成出版委員会編 : 科学的根拠に基づく急性胆管炎・胆嚢炎の診療ガイドライン.
 
12) Kim PN, et al : Gallbladder perforation : comparison of US findings with CT. Abdom Imaging 19 : 239-242, 1994.
 
13) 須藤幸一, 他 : 胆道感染症. 日本臨牀 60 : 284-288, 2002.
Medical*Online
14) American College of Physicians : Guidelines for the treatment of gallstones. Ann Intern Med 119 : 620-622, 1993.
PubMed
15) May GR, et al : Efficacy of bile acid therapy for gallstone dissolution : a meta-analysis of randomized trials. Aliment Pharmacol Ther 7 : 139-148, 1993.
PubMed
16) Podda M, et. al : Efficacy and safety of a combination of chenodeoxycholic acid and ursodeocycholic acid for gallstone dissolution : a comparison with ursodeoxycholic acid alone. Gastroenterology 96 : 222-229, 1989.
 
17) Tomida S, et al : Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones : a cohort study. Hepatology 30 : 6-13, 1999.
PubMed
18) Tazuma S, et al : A combination therapy with simvastatin and ursodeoxycolic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J Clin Gastroenterol 26 : 287-291, 1998.
 
19) Lueschner M, et al : Dissolution of gall stones with an ursodeoxycholic acid menthol preparation : a controlled prospective double blind trial. Gut 29 : 428-432, 1988.
 
20) Tuncer I, et al : The effects of ursodeoxycholic acid alone and ursodeoxycholic acid plus low-dose acetylsalicylic acid on radiolucent gallstones. Turk J Gastroenterol 14 : 91-96, 2003.
PubMed
21) Ito K, et al : Percutaneous cholecystostomy versus gallbladder aspiration for acute cholecystitis : a prospective randomized controlled trial. AJR Am J Roentgenol 183 : 193-196, 2004.
PubMed
22) 日本消化器病学会編 : 胆石症 診療ガイドライン, 2009.
 
23) 田妻進, 他 : 胆嚢摘出と胃・十二指腸機能の変化 -胆嚢温存の意義-. Prog Med 21 : 92-93, 2001.
Medical*Online
24) Vetrhus M, et al : Pain persists in many patients five years after removal of the gallbladder : observations from two randomized controlled trials of symptomatic, noncomplicated gallstone disease and acute cholecystitis. J Gastrointest Surg 9 : 826-831, 2005.
PubMed
25) 横江正道, 他 : 胆道炎ガイドラインの診断基準はCharcot3徴・Murphy徴候を超えられるか? 日本腹部救急医学会雑誌 31 : 483-487, 2011.
 
26) 鎌田研, 他 : 内視鏡的胆嚢ドレナージ術. 臨床消化器内科 4 : 445-452, 2012.
 
27) 伊神剛, 他 : 胆石症 腹腔鏡下胆嚢摘出術にどこまでこだわれるか? 肝胆膵 3 : 373-377, 2012.
 
P.195 掲載の参考文献
1) O'Connor MJ, et al : an analysis of clinical manifestation. Arch Surg 117 : 437-441, 1982.
PubMed
2) Reynolds BM, et al : Acute obstructive cholangitis ; a distinct clinical syndrome. Ann Surg 150 : 299-303, 1959.
PubMed
3) Trowbridge RL, et al : Does this patient habe acute cholecystitis? JAMA 289 : 80-86, 2003.
 
4) Boey JH, et al : Acute cholangitis. Ann Surg 211 : 264-270, 1980.
 
5) Gigot JF, et al : Acute cholangitis. Multivariate analysis of risk factors. Ann Surg 209 : 435-438, 1989.
PubMed
6) Neoptolemos JP, et al : Acute cholangitis in association with acute pancreatitis : incidence, clinical features and outcome in relation to ERCP and endoscopic sphincterotomy. Br J Surg 74 : 1103-1106, 1987.
PubMed
7) Ker CG, et al : Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma. J Gastroenterol Hepatol 6 : 505-508, 1991.
PubMed
8) Laokpessi, et al : Value of magnetic resonance cholangiography in the preoperative diagnosis of common bile duct stones. AM J Gastroenterol 96 : 2354-2359, 2001.
PubMed
9) Hanau LH, et al : Acute (ascending) cholangitis. Infect DisClin North Amer 14 : 521-546, 2000.
 
10) Sugiyama M, et al : Treatment of acute cholangitis due to choledocholithiasis in elderly and younger patients. Arch Surg 132 : 1129-1133, 1997.
PubMed
11) Kadakia SC : Biliary tract emergencies. Med Clin North Am 77 : 1015-1036, 1993.
PubMed
12) Takada T, et al : Technique and management of percutaneous tranhepaticcholangial drainage for treating an obstructive jaundice. Hepatogastroenterol 42 : 317-322, 1995.
 
13) DiSario LA, et al : Endoscopic papillary balloon dilatation compared with sphincterotomy for extraction of bile duct stones : preliminary results. Gastroenterol 127 : 1291-1299, 2004.
 
14) Tanaka S, et al : Endoscopic papillary balloon dilatation and endoscopic sphincterotomy for bile duct stones. Gastrointest Endosc 59 : 614-618, 2004.
PubMed
15) Vlavianos P, et al : Endoscopic balloon dilatation versus endoscopic sphincterotomy for the removal of bile duct stones : a prospective randomized trial. Gut 52 : 1165-1169, 2003.
 
16) Mori T, et al : Management of intrahepatic stones. Baillieres Best Pract Res Clin Gastoenterol 20 : 1117-1137, 2006.
 
P.199 掲載の参考文献
1) Segawa K, et al : Prevalence of gallbladder polyps among apparently healthy Japanese : ultrasonographic study. Am J Gastroenterol 87 : 630-633, 1992.
PubMed
2) 山雄健次, 他 : 胆嚢ポリープ (腺筋腫症を含む). 消化器病診療 良きインフォームド・コンセントに向けて (日本消化器病学会監修). pp.226-228, 医学書院, 2004.
 
3) 畑中亘, 他 : 胆嚢ポリープ. Medicina 42 : 1398-1400, 2005.
 
4) 伊佐勉, 他 : 特集・検診で発見される胆嚢ポリープの取り扱い方 長期フォローアップのしかた. 消化器の臨床 4 : 756-759, 2001.
 
5) 玉田善一, 他 : 画像からすすめる腹部疾患診療の実際 胆嚢ポリープ, 腺筋腫症. Medical Practice 22 : 1639-1643, 2005.
 
6) 土屋幸浩, 他 : 他施設集計報告. 胆嚢隆起性病変 (最大径20mm以下) 503症例の集計成績-大きさ別疾患頻度と大きさ別癌深達度-. 日消誌 83 : 2086-2087, 1986.
 
7) 藤田直哉, 他 : 検診で発見された胆嚢ポリープ, 胆嚢壁肥厚にどう対処するか? Medical Practice 22 : 255-259, 2005.
Medical*Online
8) Moriguchi H, et al : Natural history of polypoid lesions in the gallbladder. Gut 39 : 860-862, 1996.
PubMed
9) Sugiyama M, et al : Endoscopic ultrasonography for differential diagnosis of polypoid gall bladder lesions : analysis in surgical and follow up series. Gut 46 : 250-254, 2000.
PubMed
P.202 掲載の参考文献
1) 日本消化器病学会 : 消化器病診療 良きインフォームド・コンセントに向けて. pp.226-228, 医学書院, 2004.
 
2) 東京都予防医学協会年報 2012年版 pp.103-108
 
3) 生天目信之, 他 : 胆嚢腺筋腫症と胆嚢癌との関連. 胆道 22 : 181-185, 2008.
Medical*Online
4) 日本癌治療学会 : がん診療ガイドライン.
 
5) 内村正幸, 他 : 胆嚢のadenomyomatosis. 胆と膵 9 : 891-900, 1988.
 
P.208 掲載の参考文献
1) 日本肝癌研究会 : 原発性肝癌取扱い規約. 第5版補訂版, 2009.
 
2) 日本胆道外科研究会 : 胆道癌取扱い規約. 第5版, 2003.
 
3) 胆道癌診療ガイドライン作成出版委員会 : エビデンスに基づいた胆道癌診療ガイドライン. 第1版, 2007.
 
4) Nagakawa T, et al : Biliary tract cancer treatment : results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg 9 : 569-575, 2002.
PubMed
5) Miyakawa S, et al : Biliary tract cancer treatment : 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 16 : 1-7, 2009.
PubMed
6) Valle J, et al : Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362 : 1273-1281, 2010.
PubMed
7) Okusaka T, et al : Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan. Br J Cancer 103 : 469-474, 2010.
 
8) Sasaki T, et al : Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 65 : 1101-1107, 2010.
PubMed
9) Kanai M, et al : A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 67 : 1429-1434, 2010.
PubMed
10) Ueno H, et al : Phase II study of S-1 in patients with advanced biliary tract cancer 91 : 1769-1774, 2004.
PubMed
11) Furuse J, et al : S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer : a multicenter phase II study 62 : 849-855, 2008.
PubMed

3章 膵疾患

P.221 掲載の参考文献
1) 急性膵炎診療ガイドライン2010 改訂出版委員会 : 急性膵炎診療ガイドライン2010. 金原出版, 2009.
 
2) 武田和憲, 他 : 急性膵炎重症度判定基準最終改訂案の検証. 厚生労働科学研究費補助金難治性疾患克服研究事業難治性膵疾患に関する調査研究, 平成19年度総括・分担研究報告書. 29-33, 2008.
 
3) Jakobs R, et al : Buprenorphine or procaine for pain relief in acute pancreatitis. A prospective randomized study. Scand J Gastroenterol 35 : 1319-1323, 2000.
PubMed
4) Kahl S, et al : Procaine hydrochloride fails to relieve pain in patients with acute pancreatitis. Digestion 69 : 5-9, 2004.
PubMed
5) Buchler M, et al : Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology 103 : 1902-1908, 1992.
PubMed
6) Rokke O, et al : Early treatment of severe pancreatitis with imipenem : A prospective randomized clinical trial. Scand J Gastroenterol 42 : 771-776, 2007.
PubMed
7) Manes G, et al : Prophylaxis with meropenem of septic complications in acute pancreatitis : a randomized, controlled trial versus imipenem. Pancreas 27 : e79-e83, 2003.
PubMed
8) Seta T, et al : Treatment of acute pancreatitis with protease inhibitors : a meta-analysis. Eur J Gastroenterol Hepatol 16 : 1287-1293, 2004.
PubMed
9) Pezzilli R, et al : Multicentre comparative study of two schedules of gabexate mesilate in the treatment of acute pancreatitis. Italian Acute Pancreatitis Study Group. Dig Liver Dis 33 : 49-57, 2001.
 
10) Sax HC, et al : Early total parenteral nutrition in acute pancreatitis : lack of beneficial effects. Am J Surg 153 : 117-124, 1987.
PubMed
11) Petrov MS, et al : A randomized controlled trial of enteral versus parenteral feeding in patients with predicted severe acute pancreatitis shows a significant reduction in mortality and in infected pancreatic complications with total enteral nutrition. Dig Surg 23 : 336-344, 2006.
 
12) Gupta R, et al : A randomised clinical trial to assess the effect of total enteral and total parenteral nutritional support on metabolic, inflammatory and oxidative markers in patients with predicted severe acute pancreatitis (APACHE II > or = 6). Pancreatology 3 : 406-413, 2003.
PubMed
13) Petrov MS, et al : Nasogastric tube feeding in predicted severe acute pancreatitis. A systematic review of the literature to determine safety and tolerance. JOP 9 : 440-448, 2008.
PubMed
14) Luiten EJ, et al : Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis. Ann Surg 222 : 57-65, 1995.
PubMed
15) Mayer AD, et al : Continuous clinical trial of peritoneal lavage for the treatment of severe acute pancreatitis. N Engl J Med 312 : 399-404, 1985.
 
16) 平澤博之, 他 : 重症急性膵炎におけるhumoral mediatorからみた持続的血液濾過透析 (CHDF) の有効性に関する検討. 厚生省特定疾患対策事業重症急性膵炎の救命率を改善するための研究班, 平成11年度研究報告書. 162-170, 2000.
 
17) Takeda K, et al : Benefit of continuous regional arterial infusion of protease inhibitor and antibiotic in the management of acute necrotizing pancreatitis. Pancreatology 1 : 668-673, 2001.
PubMed
18) Rau B, et al : Surgical treatment of necrotizing pancreatitis by necrosectomy and closed lavage : changing patient characteristics and outcome in a 19-year, single-center series. Surgery 138 : 28-39, 2005.
 
19) Nathens AB, et al : Management of the critically ill patient with severe acute pancreatitis. Crit Care Med 32 : 2524-2536, 2004.
PubMed
20) Baril NB, et al : Does an infected peripancreatic fluid collection or abscess mandate operation? Ann Surg 231 : 361-367, 2000.
PubMed
21) Singh P, et al : Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 60 : 554-550, 2004.
 
22) Crippa S, et al : Rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 367 : 278, 2012.
PubMed
23) Zheng M, et al : Gabexate in the prophylaxis of post-ERCP pancreatitis : a meta-analysis of randomized controlled trials. BMC Gastroenterol 7 : 6-13, 2007.
PubMed
24) Manes G, et al : Efficacy of postprocedure administration of gabexate mesilate in the prevention of post-ERCP pancreatitis : a randomized, controlled, multicenter study. Gastrointest Endosc 65 : 982-987, 2007.
PubMed
25) Oruc N, et al : Infliximab : a new therapeutic agent in acute pancreatitis? Pancreas 28 : e1-8, 2004.
PubMed
26) Michel Kahaleh : Endoscopic necrosectomy for walled-off pancreatic necrosis. Clin Endosc 45 : 313-315, 2012.
PubMed
P.230 掲載の参考文献
1) 厚生労働省難治性膵疾患に関する調査研究班, 日本膵臓学会, 日本消化器病学会 : 慢性膵炎臨床診断基準2009. 膵臓 24 : 645-646, 2009.
Medical*Online
2) 下瀬川徹, 他 : 慢性膵炎の実態に関する全国調査. 厚生労働科学研究費助成金「難治性膵疾患に関する調査研究」平成20年度～22年度 総合研究報告書 185-189, 2011.
 
3) 日本消化器病学会 : 慢性膵炎診療ガイドライン, 2009.
 
4) 武内正, 他 : 薬の知識. パンクレリパーゼ (リパクレオン). 臨床内科 27 : 383-386, 2012.
 
5) 山口武人 : 内視鏡治療の限界-ESWL併用を含めて-. 胆肝膵 64 : 901-906, 2012.
 
6) 川口義明, 他 : 再発性膵炎に対する内視鏡的ステント留置法の現状. 胆と膵 33 : 357-365, 2012.
 
P.241 掲載の参考文献
1) Ogawa Y, et al : A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer 94 : 2344-2349, 2002.
PubMed
2) 中原一有, 他 : 経過中に膵癌を発症した慢性膵炎症例の臨床像. 胆と膵 29 : 253-258, 2008.
Medical*Online
3) 池永直樹, 他 : 膵癌 疫学・危険因子・症候. 日本内科学会雑誌 101 : 4-6, 2012.
 
4) 高山玲子, 他 : 画像診断 ; EUS. Pharma Medica 26 : 35-38, 2008.
Medical*Online
5) Iiboshi T, et al : Value of cytodiagnosis using endoscopic nasopancreatic drainage for early diagnosis of pancreatic cancer : establishing a new method for the early detection of pancreatic carcinoma in situ. Pancreas 41 : 523-529, 2012.
PubMed
6) 日本膵臓学会 : 膵癌取扱い規約, 第6版, p.11, 金原出版, 2009.
 
7) 田中雅夫 : 膵癌登録報告2007. 膵臓 22 : e133, 2007.
 
8) Moore MJ, et al : Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol 25 : 1960-1966, 2007.
 
9) Conroy T, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 : 1817-1825, 2011.
PubMed
10) Damerla V, et al : Pancreatic enzyme supplementation in pancreatic cancer. J Support Oncol 6 : 393-396, 2008.
PubMed
P.250 掲載の参考文献
1) Tanaka M, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
2) Uehara H, et al : Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut 57 : 1561-1565, 2008.
PubMed
3) Tanno S, et al : Pancreatic ductal adenocarcinoma in long-term follow-up patients with branch duct intraductal papillary mucinous neoplasms. Pancreas 39 : 36-40, 2010.
PubMed
4) Kawakubo K, et al : Incidence of extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasms of the pancreas. Gut 60 : 1249-1253, 2011.
PubMed
5) Tanaka M, et al : International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
PubMed
6) 鈴木裕, 他 : IPMT, MCTにおける全国症例調査の分析と現状における問題点. 膵臓 18 : 653-663, 2003.
Medical*Online
7) Zamboni G, et al : Mucinous cystic tumors of the pancreas. Am J Surg Pathol 23 : 410-422, 1999.
PubMed
8) Suzuki Y, et al : Cystic neoplasm of the pancreas : a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 28 : 241-246, 2004.
PubMed
9) 山雄健次 : 膵管内乳頭腫瘍と粘液性嚢胞腫瘍の臨床診断. 消化器画像 3 : 322-328, 2001.
 
10) Galanis C, et al : Resected serous cystic neoplasms of the pancreas : A review of 158 patients with recommendations for treatment. J Gastrointest Surg 11 : 820-826, 2007.
PubMed
11) 渡辺五郎, 他 : Serous Cystic Tumor (SCT) の手術適応-自験例17例の検討と手術適応についての考察. 胆と膵 24 : 303-310, 2003.
 
12) 吉岡正智, 他 : 膵solid-pseudopapillary tumorの臨床病理学的特徴と外科的治療-本邦報告302例と自験6例について-. 胆と膵 22 : 45-52, 2002.
 
13) 杉山政則, 他 : 膵嚢胞性腫瘍の治療方針. 日消病会誌 101 : 865-71, 2004.
 
14) Bladley EL, et al : The natural history of pancreatic pseudocyst : A unified concept of management. Am J Surg 137 : 135-139, 1979.
 
15) 乾和郎, 他 : 膵仮性嚢胞の内視鏡治療ガイドライン2009. 膵臓 24 : 571-593, 2009.
Medical*Online
P.255 掲載の参考文献
1) 厚生労働省難治性膵疾患調査研究班・日本膵臓学会 : 自己免疫性膵炎診療ガイドライン2009. 膵臓 24 : 1-54, 2009.
 
2) Shimosegawa T, et al : International consensus diagnostic criteria for autoimmune pancreatitis : guidelines of the International Association of Pancreatology. Pancreas 40 : 352-358, 2011.
PubMed
3) 日本膵臓学会・厚生労働省難治性膵疾患調査研究班 : 自己免疫性膵炎臨床診断基準2011. 膵臓 27 : 17-25, 2012.
 
4) 西森功, 他 : 自己免疫性膵炎の実態調査 (第2回全国調査) 平成21年度厚生労働省難治性膵疾患調査研究報告書. 222-225, 2010.
 
5) 西森功, 他 : 自己免疫性膵炎の治療についての実態調査. 胆と膵 28 : 961-966, 2007.
Medical*Online
P.259 掲載の参考文献
1) Halfdanarson T, et al : Pancreatic endocrine neoplasms : epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer 15 : 409-427, 2008.
PubMed
2) Ito T, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.
PubMed
3) Alexakis N et al : Hereditary pancreatic endocrine tumors. Pancreatology 4 : 417-435, 2004.
PubMed
4) Oberg K, et al : Consensus report on the use of somatostatin analogs for the managements of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncology 15 : 966-973, 2004.
PubMed
5) Bosman FT, et al : WHO classification of Tumors of Digestive System Eds : 4th Edition, 2010 LARC Press, lyons France.
 
6) Rindi G, et al : TNM staging go foregut (neuro) endocrine tumors : a consensus proposal including a grading system Virchows Arch 449 : 395-401, 2006.
 
7) Moertel CG, et al : Streptozocin-doxorubicin, streptoaocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 : 529-523, 1992.
 
8) Rinke A, et al : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group.J Clin Oncol 27 : 4656-4663, 2009.
 
9) Raymond E, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364 : 501-513, 2011.
PubMed
10) Yao JC, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364 : 514-523, 2011.
PubMed

4章 食道疾患

P.266 掲載の参考文献
1) Vakiol N, et al : The Montreal definition and classification of gastroesophageal refulux disease : a global evidence-based consensus. Am J Gastroenterol 101 : 1900-1920 ; quiz 1943, 2006.
 
2) Fass R, et al : Systematic review : proton-pump inhibitor failure in gastro-oesophageal refulux disease-where next? Aliment Parmacol Ther 22 : 79-94, 2005.
 
3) Xenos ES : The role of esophageal motility and hiatal hernia in esophageal exposure to acid. Surg Endsc 16 : 914-920, 2002.
 
4) 草野元康, 他 : 日本人の食道裂孔ヘルニアの頻度. Gastroenterol Endsc 47 : 962-973, 2005.
 
5) GERD研究会 : GERD Guidline Workshop Report 2002. 2002.
 
6) Hongo M : Review article : Barrett's oesophagus and carcinoma in Japan. Aliment Parmacol Ther 20 : 50-54, 2004.
 
7) 吉田智治, 他 : 問診による逆流性食道炎およびGERDの診断. 日臨 62 : 1455-1458, 2004.
Medical*Online
8) Armstrong D, et al : The endoscopic assessment of esophagitis : a progress report on obserber agreement. Gastroenterology 111 : 85-92, 1996.
PubMed
9) Lundell LR, et al : Endoscopic assessment of oesophagitis : clinical and functional correlates and further validation of the Los Angeles classification. Gut 45 : 172-180, 1999.
PubMed
10) Hoshihara Y : Endoscopic findings of GERD. Nihon Rinsho 62 : 1459-1464, 2004.
PubMed
11) Johnsson F, et al : One-week omeprazole treatment in the diagnosis of gastrooesophageal reflux disease. Scand J Gastroenterol 33 : 15-20, 1998.
PubMed
12) Klinkenberg-Knol EC, et al : Combined gastric and oesophageal 24-houe pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment Pharmacol Ther 4 : 485-489, 1990.
 
13) Wiener GJ, et al : The symptom index : a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol 83 : 358-361, 1988.
PubMed
14) Breumelhof R, et al : The symptom sensitivity index : a valuable additional parameter in 24-hour esophageal pH recording. Am J Gastroenterol 86 : 160-164, 1991.
PubMed
15) Weuten BL, et al : The symptom-assosiation probability : an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 107 : 1741-1745, 1994.
 
16) des Varannes SB, et al : Simultaneous recordings of oesophageal acid exposure with conventional pH monitoring and a wireless system (Bravo). Gut 54 : 1682-1686, 2005.
 
17) Wang KK, et al : American Gastroenterological Association technical review on the role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology 128 : 1471-1505, 2005.
PubMed
18) Guelrud M, et al : Enhanced magnification endoscopy : a new technique to idenitify specialized intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 64 : 559-565, 2001.
 
19) Mannath J, et al : Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barrett's esophagus : a meta-analysis. Endoscopy 42 : 351-359, 2010.
PubMed
20) Holloway RH, et al : Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 38 : 649-654, 1996.
PubMed
21) Gote GA, et al : Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 10 : 208-214, 2008.
 
22) Anvari M, et al : A randomized controlled trial of laparoscopic nissen fundoplication versus proton pump inhibitors for treatment of patients with chronic gastroesophageal reflex disease : one-year forrow-up.Surg Innov 13 : 238-249, 2006.
 
23) Chadalavada R, et al : Comparative results of endoluminal gastroplasty and laparoscopic antireflex surgery for the treatment of GERD. Surg Endosc 18 : 261-165, 2004.
 
24) Hofstetter WL, et al : Long-term outcome of antireflex surgery in patients with Barrett's esophagus. Ann Surg 234 : 532-538, 2001.
 
25) Shaheen NJ, et al : Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 360 : 2277-2288, 2009.
PubMed
P.282 掲載の参考文献
1) 日本門脈圧亢進症学会 : 門脈圧亢進症取扱い規約. 第2版, 巻頭挿絵, 金原出版, 2004.
 
2) Carbonell N, et al : Improved survival after variceal bleeding in patients with cirrhosis over the past two decade. Hepatology 40 : 652-659, 2004.
PubMed
3) ASGE Guideline : the role of endoscopy in the management of variceal hemorrhage, updated July 2005. Gastrointest Endosc 62 : 651-655, 2005.
PubMed
4) 小原勝敏, 他 : 食道・胃静脈瘤内視鏡治療ガイドライン (日本消化器内視鏡学会卒後教育委員会編 : 消化器内視鏡ガイドライン). 第3版, pp215-233, 医学書院, 2006.
 
5) 日本門脈圧亢進症学会 : 門脈圧亢進症取扱い規約. 第2版, pp.37-50, 金原出版, 2004.
 
6) Chavez-Tapia NC, et al : Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev, 2010. CD002907.
PubMed
7) Renner E : WGO-OMGE Practice Guideline : Treatment of Esophageal Varices (www.omge.org/), World Gastroenterology Organization, 2003.
 
8) 杉原桂蔵, 他 : 門脈血行異常症 (門脈圧亢進症) による上部消化管出血に対する塩酸プロプラノロールの予防効果および安全性の検討. 肝臓 45 : 248-260, 2004.
 
9) Gluud LL, et al : Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices : Systematic review of randomized trials. Am J. Gastroenterol 102 : 2842-2848, 2007.
PubMed
10) Khuroo MS, et al : Meta-analysis endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleedingligation. Aliment Pharmacolo Ther 21 : 347-361, 2005.
 
11) Garcia-Tsao G, et al : Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis. Hepatology 46 : 922-938, 2007.
PubMed
12) Nakamura S, et al : Endoscopic induction of mucosal fibrosis by argon plasma coagulation (APC) for esophageal varices : a prospective randomized control trial of ligation plus APC vs ligation alone. Endoscopy 33 : 210-215, 2001.
 
13) 萩原優, 他 : 高度食道静脈瘤に対する予防的硬化療法の無作為比較臨床試験. 日本門脈圧亢進症学会雑誌 7 : 140-145, 2001.
 
14) Tomikawa M, et al : Endoscopic injection sclerotherapy in management of 2105 patients with esophageal varices. Surgery 131 : S171-175, 2002.
PubMed
15) Okano H, et al : Long-term follow-up of patients with liver cirrhosis after endoscopic ethanol injection sclerotherapy for esophageal varices. Hepatogastroenterol 50 : 1556-1559, 2003.
 
16) Svoboda P, et al : A prospective randomized control trial of sclerotherapy vs ligation in the prophylactic treatment of high-risk esophageal varices. Surg Endosc 13 : 580-584, 1999.
PubMed
17) Masumoto H, et al : Ligation plus low-volume sclerotherapy for high-risk esophageal varices : comparisons with ligation therapy or sclerotherapy alone. J Gastroenterol 33 : 1-5, 1998.
PubMed
18) Laine L, et al : Endoscopic Ligation Compared with Sclerotharapy for Treatment Esophageal Variceal Bleeding. Ann Intern Med 123 : 280-287, 1995.
 
19) Avgerinos A, et al : Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis. Hepatology 39 : 1623-1630, 2004.
 
20) Cipolletta L, et al : Argon plasma coagulation prevents variceal recurrence after band ligation of esophageal varices : preliminary results of a prospective randomized trial. Gastrointest Endosc 56 : 467-471, 2002.
PubMed
21) Singh P, et al : Combined ligation and sclerotherapy versus ligation alone for secondary prophylaxis of esophageal variceal bleeding : meta-analysis. Am J Gastroenterol 97 : 623-629, 2002.
PubMed
22) Ravipati M, et al : Pharmacotherapy plus endoscopic intervention is more effective than pharmacotherapy or endoscopy alone in the secondary prevention of esophageal variceal bleeding : a meta-analysis of randomized, controlled trials. Gastrointest Endosc 70 : 658-664, 2009.
PubMed
23) Lo GH, et al : A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 33 : 1060-1064, 2001.
PubMed
24) Sarin SK, et al : A randomized controlled trial of cyanoacrylate versus alchol injection in patients with asolated fundic varices. Am J Gastroenterol 97 : 1010-1015, 2002.
 
25) 出月康夫, 他 : 食道静脈瘤に対する治療法の現況 -全国アンケート調査の集計. 日本医事新報 3517 : 23-29, 1991.
 
26) Irisawa A, et al : Endoscopic recurrence of esophageal varices is associated with the specific EUS abnormalities : severe peri-esophageal collateral veins and large perforating veins. Gastrointest Endos 53 : 77-84, 2001.
 
27) Andres C, et al : Management of patients with cirrhosis awaiting liver transplantation. Gut 60 : 412-421, 2011.
 
P.291 掲載の参考文献
1) Ozawa S, et al : Comprehensive registry of esophageal cancer in Japan, 2002. Esophagus 7 : 7-22, 2002.
 
2) Yokoyama A, et al : Generic polymorphisms of alcohol and aldehyde dehydrogenases and glutathione S-transferase M1 and drinking, smoking, and diet in Japanese men with esophageal squamous cell carcinoma. Carcinogenesis 23 : 1851-1859, 2002.
PubMed
3) Muto M, et al : Early detection of superficial squamous cell carcinomain the head and neck region and esophagus by narrow band imaging : a multicenter randomized controlled trial. J Clin Oncol. 28 : 1566-1572, 2010.
 
4) 有馬美和子, 他 : 食道癌表在癌深達度診断の進歩. 胃と腸 41 : 183-195, 2006.
 
5) 日本食道学会 : 食道癌診断・治療ガイドライン, 2012年4月版.
 
6) Savary JF, et al : Photodynamic therapy of early squamous cell carcinomas of the esophagus : a review of 31 cases. Endoscopy 30 : 258-265, 1998.
PubMed
7) Tahara K, et al : Argon plasma coagulation for superficial esophageal squamous-cell carcinoma in high-risk patients. World J Gastroenterol 18 : 5412-5417, 2012.
PubMed
8) 門馬久美子, 他 : 食道癌に対する内視鏡的粘膜切除. 癌と化学療法 30 : 914-919, 2003.
Medical*Online
9) 小山恒男, 他 : 第46回食道色素研究会アンケート調査報告 (転移のあったm3・sm1食道癌の特徴). 胃と腸 37 : 71-74, 2002.
 
10) 鍋谷圭宏, 他 : EBMのための内科疾患データファイル-食道癌. 内科 89 : 1093-1097, 2002.
 
11) Group MRCOCW : Surgical resection with or without preoperative chemotherapy in oesophageal cancer : a randomized controlled trial. Lancet 359 ; 1727-1733, 2002
 
12) Ando N, et al : A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19 : 68-74, 2012.
 
13) Ando N, et al : Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus : A Japan Clinical Oncology Group Study (JCOG9204). J Clin Oncol 21 : 4592-4596, 2003.
 
14) Iizuka T, et al : Phase II evaluation of cisplatin and 5-fuluorouracil in advanced squamous cell carcinoma of the esophagus : a Japanese Esophageal Oncology Group trial. Jpn J Clin Oncol 22 : 172-176, 1992.
 
15) al-Sarraf M, et al : Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer : an intergroup study. J Clin Oncol 15 ; 277-284, 1997.
PubMed
16) Kato H, et al : A phase II trial of chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma : Japan Clinical Oncology Group study (JCOG9708). Proc Am Soc Clin Oncol 22 : 286, 2003.
 
17) Ohtsu A, et al : Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17 : 2915-21, 1999
 
P.295 掲載の参考文献
1) 日本食道学会 : 食道アカラシア取扱い規約. 第4版, 金原出版, 2012.
 
2) Hirota WK, et al : ASGE guideline : the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 63 : 570-580, 2006.
PubMed
3) Boeckxstaens GE, et al : Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia. N Engl J Med 364 : 1807-1816, 2011.
PubMed
4) Pasricha PJ, et al : Botulinum toxin for the treatment of achalasia. N Engl J Med 322 : 774-778, 1995.
 
5) Inoue H, et al : Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 42 : 265-271, 2010.
PubMed

5章 胃・十二指腸疾患

P.301 掲載の参考文献
1) Misiewicz JJ : The Sydney System : A new classification of gastritis. Introduction. J Gastroenterol Hepatol 6 : 207-208, 1991.
PubMed
2) Dixon MF, et al : Classification and grading of gastritis : The Updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20 : 1161-1181, 1996.
PubMed
3) Yasunaga Y, et al : Improved fold width and increased acid secretion after eradication of the organism in Helicobacter pylori associated enlarged fold gastritis. Gut 35 : 1571-1574, 1994.
PubMed
4) 鎌田智有, 他 : 木村・竹本分類. 胃と腸 47 : 852, 2012.
 
P.310 掲載の参考文献
1) Asaka M, et al : Guideline in the management of Helicobacter pylori infection in Japan. Helicobacter 6 : 177-186, 2001.
PubMed
2) Kohler B, et al : Upper GI-bleeding - value and consequences of emergency endoscopy and endoscopic treatment. Hepatogastroenterology 38 : 198-200, 1991.
PubMed
3) Rostom A, et al : Preventiou of NSAID-induced gastroduodenal ulcer. Cochrane Database Syst Rev 4 : CD002296, 2000.
 
4) Vergara M, et al : Meta-analysis : role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 21 : 1411-1418, 2005.
PubMed
5) Ford AC, et al : Eradication therapy in Helicobacter pylori positive peptic ulcer disease : systematic review and economic analysis. Am J Gastroenterol 99 : 1833-1855, 2004.
PubMed
6) Fukase K, et al : Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer : an open-label, randocised controlled trial. Lancet 372 : 392-397, 2008.
PubMed
P.315 掲載の参考文献
1) 大倉康男, 他 : IV. ポリープ (中村眞一編 : 消化管病理標本の読み方). p.53-55, 日本メディカルセンター, 2008.
 
2) 八尾隆史, 他 : 【胃ポリープの意義と鑑別】胃ポリープの病理学的分類・鑑別診断と臨床的意義. 胃と腸 47 : 1192-1199, 2012.
 
3) 山田達哉, 他 : 胃隆起性病変. 胃と腸 1 : 43-48, 1966.
 
4) 日本胃癌学会 : 胃癌取扱い規約, 第14版, 2010.
Medical*Online
5) Kato M, et al. Endoscopic submucosal dissection as a treatment for gastric noninvasive neoplasia : a multicenter study by Osaka University ESD Study Group.J Gastroenterol 46 : 325-331, 2011.
 
P.323 掲載の参考文献
1) 川口実 : GISTの臨床的対応-粘膜下腫瘍におけるGISTの頻度と臨床的取り扱い. 胃と腸 36 : 1137-1145, 2001.
 
2) Kinoshita K, et al : Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. J Pathol 202 : 80-85, 2004.
PubMed
3) Dematteo RP, et al : American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour : a randomised, double-blind, placebocontrolled trial. Lancet 373 : 1097-1104, 2009.
 
4) Joensuu H, et al : Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence : final results of a randomized trial (SSGXVIII/AIO) [abstr] . J Clin Oncol 29, 2011.
 
P.334 掲載の参考文献
1) 厚生労働省 : 人口動態統計年報. Available from : http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/suii10/index.html.
 
2) 日本胃癌学会 : 胃癌取扱い規約, 第14版, 2010.
Medical*Online
3) Isobe Y, et al : Gastric cancer treatment in Japan : 2008 annual report of the JGCA nationwide registry. Gastric Cancer 14 : 301-316, 2011.
PubMed
4) 平成18年度厚生労働省がん研究助成金「がん検診の適切な方法とその評価法の確立に関する研究」班 : 有効性評価に基づく胃がん検診ガイドライン, 2006.
 
5) Fukase K, et al : Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer : an open-label, randomised controlled trial. Lancet 372 : 392-397, 2008.
PubMed
6) Sakuramoto S, et al : Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357 : 1810-1820, 2007.
 
7) Sasako M, et al : Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29 : 4387-4393, 2011.
PubMed
8) Boku N, et al : Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer : a randomised phase 3 study. Lancet Oncol 10 : 1063-1069, 2009.
PubMed
9) Koizumi W, et al : S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial) : a phase III trial. Lancet Oncol 9 : 215-221, 2008.
 
10) Takashima A, et al : Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis. J Cancer Res Clin Oncol 136 : 243-248, 2010.
PubMed
11) Ezoe Y, et al : Magnifying narrowband imaging is more accurate than conventional white-light imaging in diagnosis of gastric mucosal cancer. Gastroenterology 141 : 2017-2025 , 2011.
PubMed
12) Gotoda T, et al : Incidence of lymph node metastasis from early gastric cancer : estimation with a large number of cases at two large centers. Gastric Cancer 3 : 219-225, 2000.
 
13) Hirasawa T, et al : Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. Gastric Cancer 12 : 148-152, 2009.
PubMed
14) Kato M, et al : Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer : a multicentre retrospective cohort study by Osaka University ESD study group.Gut , 2012.
 
P.342 掲載の参考文献
1) Freeman C, et al : Occurrence and prognosis of extranodal lymphoma. Cancer 29 : 252-260, 1972.
PubMed
2) Swerdlow SH, et al : WHO classification of tumors of haematopoietic and lymphoid tissues (4th ed.). Lyon, IARC Press, 2008.
 
3) d'Amore F, et al : Non-Hodgkin's lymphoma of the gastrointestinal tract : a populationbased analysis of incidence, geographic features, and prognosis. J Clin Oncol 12 : 1673-1684, 1994.
PubMed
4) 飯田三雄, 他 : 小腸悪性リンパ腫. 胃と腸アトラス I. 医学書院, p66-69, 2001.
 
5) 吉野正, 他 : 腸管悪性リンパ腫の分子病理学的特徴. 胃と腸 41 : 295-303, 2006.
 
6) Akagi T. et al : A novel gene, MALT1 at 18q21, is involved in t (11 ; 18) (q21 ; q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18 : 5785-5794. 1999.
 
7) Rohatiner A, et al : Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 5 : 397-400, 1994.
PubMed
8) Nakamura S, et al : Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut 48 : 454-460, 2001.
PubMed
9) Andrew DZ, et al : NCCN Clinical Practive Guidelines in Oncology, Non-Hodgkin's lymphomas version 3. 2012.
 
10) 日本ヘリコバクター学会 : H. pylori感染の診断と治療のガイドライン -改訂版-, 2003.
 
11) 小椋美知則 : 腸管悪性リンパ腫の治療-内科的治療 胃と腸 41 : 338-344, 2006.
 
12) Coiffier B, et al : CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Eng J Med 346 : 235-242, 2002.
 
13) Mac Manus MP, et al : Is radiotherapy curative for stage 1 and 2 low grade follicular lymphoma : report from a single-institutional prospectibe study. J Clin Oncol 14 : 1282, 1996.
 
14) 田近正洋, 他 : 除菌後の胃MALTリンパ腫の長期経過. 日本臨床 63 : 516-519, 2005.
Medical*Online
15) Akamatsu T, et al : Comparison of localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma with and without Helicobacter pylori infection. Helicobacter 11 : 86-95, 2006.
PubMed
16) Raderer M, et al : Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 65 : 306-310, 2003.
PubMed
P.348 掲載の参考文献
1) Thompson WG : Nonulcer dyspepsia. Can Med Assoc J 130 : 565-569, 1984.
PubMed
2) Tack J, et al : Functional gastrodudenal disorders. Gastroenterology 130 : 1466-1479, 2006.
 
3) Tahara T, et al : Association of endoscopic appearances with dyspeptic symptoms. J Gastoenterol 43 : 208-215, 2008.
 
4) Henry P, et al : American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenteorology 127 : 1592-1622, 2004.
 
5) Talley NJ : American Gastroenterological Association. American Gastroenterological Association medical position statement : evaluation of dyspepsia. Gastroenterology 129 : 1753-1755, 2005.
 
6) Wang WH, et al : Effects of proton-pump inhibitors on functional dyspepsia : a metaanalysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol 5 : 178-185, 2007.
PubMed
7) Veldhuyzen van Zanten SJ, et al : Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia : a meta-analysis. Am J Gastroenterol 96 : 689-696, 2001.
PubMed
8) Hongo M, et al : Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone : Japan Mosapride Mega-Study (JMMS). J Gastroenterol Hepatol 27 : 62-68, 2012.
PubMed
9) Hojo M, et al : Treatment of functional dyspepsia with antianxiety or antidepressive agents : systematic review. J Gastroenterol 40 : 1036-1042, 2005.
 
10) Geeraerts B, et al : Functional dyspepsia : past, present, and future. J Gastroenterol 43 : 251-255, 2008.
PubMed

6章 腸疾患

P.353 掲載の参考文献
1) Iddan G, et al : Wireless capsule endoscopy. Nature 405 : 417, 2000.
PubMed
2) Yamamoto H, et al : Total enteroscopy with a nonsurgical steerable doubleballoonmethod. Gastrointest Endosc 53 : 216-220, 2001.
PubMed
3) Szold A, et al : Surgical approach to occult gastrointestinal bleeding. Am J Surg 163 : 90-92, 1992.
PubMed
4) Pasha SF, et al : Diagnostic evaluation and management of obscure gastrointestinal bleeding : a changing paradigm. Gastroenterol hepatol 5 : 839-850, 2009.
PubMed
5) Yano T, et al : Endoscopic classification of vascular lesions of the small intestine (with videos). Gastrointest Endosc 67 : 169-172, 2008.
PubMed
6) Mitsui K, et al : Role of double-balloon endoscopy in the diagnosis of small-bowel tumors : the first Japanese multicenter study. Gastrointest Endosc 70 : 498-504, 2009.
PubMed
7) 大宮直木, 他 : 小さな小腸病変に対するカプセル内視鏡, ダブルバルーン内視鏡, 小腸X線の診断能の比較. 胃と腸 44 : 1021-1028, 2009.
 
8) Leighton JA : The Role of Endoscopic Imaging of the Small Bowel in Clinical Practice. Am J Gastroenterol 106 : 27-36, 2011.
PubMed
9) Raju GS, et al : American Gastroenterological Association : American Gastroenterological Association (AGA) Institute medical position statement on obscure gastrointestinal bleeding. Gastroenterology 133 : 1694-1696, 2007.
 
P.364 掲載の参考文献
1) 潰瘍性大腸炎・クローン病診断基準・治療指針 厚生労働科学研究費補助金 難治性疾患克服研究事業「難治性炎症性腸管障害に関する調査研究」班 (渡辺班) 平成23年度分担研究報告書 別冊 (平成24年7月) : 15-20, 2012.
 
2) Takagi S, et al : Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease : A randomized-controlled trial. Aliment Pharmacol Ther 24 : 1333-1340, 2006.
PubMed
3) Summers RW, et al : National Cooperative Crohn's Disease Study : results of drug treatment. Gastroenterology 77 : 847-869, 1979.
PubMed
4) Present DH, et al : Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 302 : 981-987, 1980.
PubMed
5) Francella A, et al : The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease : a retrospective cohort study. Gastroenterology 124 : 9-17, 2003.
PubMed
6) Ford AC, et al : Efficacy of biological therapies in inflammatory bowel disease : systematic review and meta-analysis. Am J Gastroenterol 106 : 644-659, 2011.
PubMed
7) D'Haens G, et al : Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease : an open randomised trial. Lancet 371 : 660-667, 2008.
 
8) 免疫抑制・化学療法により発症するB型肝炎対策ガイドライン (改訂版) 厚生労働科学研究費補助金 肝炎等克服緊急対策研究事業「ウイルス性肝炎における最新の治療法の標準化を目指す研究」班による平成24年B型C型慢性肝炎・肝硬変治療ガイドライン : 18-19, 2012.
 
9) Colombel JF, et al : Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362 : 1383-1395, 2010.
 
10) Fukuda Y, et al : Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease : an open multicenter prospective study. J Gastroenterol 39 : 1158-1164, 2004.
PubMed
11) Regueiro M, et al : Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 136 : 441-450, 2009.
PubMed
12) Yamamoto T, et al : Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease : a prospective pilot study. Inflamm Bowel Dis 15 : 1460-1466, 2009.
PubMed
13) Hirai F, et al : Endoscopic balloon dilatation using double-balloon endoscopy is a useful and safe treatment for small intestinal strictures in Crohn's disease. Dig Endosc 22 : 200-204, 2010.
PubMed
14) Sandborn WJ, et al : Adalimumab for maintenance treatment of Crohn's disease : results of the CLASSIC II trial. Gut 56 : 1232-1239, 2007.
PubMed
15) Hanauer SB, et al : Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease : the CLASSIC-I trial. Gastroenterology 130 : 323-333 ; quiz 591, 2006.
PubMed
16) Rutgeerts P, et al : Adalimumab induces and maintains mucosal healing in patients with Crohn's disease : data from the EXTEND trial. Gastroenterology 142 : 1102-1111, 2012.
PubMed
17) Sandborn WJ, et al : Adalimumab induction therapy for Crohn disease previously treated with infliximab : a randomized trial. Ann Intern Med 146 : 829-338, 2007.
PubMed
18) Lichtiger S, et al : The CHOICE trial : adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 32 : 1228-1239, 2010.
PubMed
P.377 掲載の参考文献
1) 難治性炎症性腸管障害に関する調査研究班 (渡辺班) 平成23年度改訂版 : 潰瘍性大腸炎・クローン病診断基準・治療指針, 2011
 
2) Baumgart DC, et al : Inflammatory bowel disease. Lancet 369 : 1627-1640, 2007.
PubMed
3) Jowett SL, et al : Influence of dietary factors on the clinical course of ulcerative colitis : a prospective cohort study. Gut 53 : 1479-1484, 2004.
PubMed
4) 難治性炎症性腸管障害に関する調査研究班 プロジェクト研究グループ : エビデンスとコンセンサスを統合した潰瘍性大腸炎の診療ガイドライン, 2006.
 
5) Rachmilewitz D, et al : Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis : a randomised trial. BMJ 298 : 82-86, 1989.
PubMed
6) Schroeder KW, et al : Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317 : 1625-1629, 1987.
PubMed
7) Matts, SGF : The value of rectal biopsy in the diagnosis of ulcerative colitis. Quart J Med 30 : 393-407, 1961.
 
8) Truelove SC, et al : Cortisone in ulcerative colitis ; final report on a therapeutic trial. Br Med J 2 : 1041-1048, 1955.
PubMed
9) Sandborn WJ, et al : Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142 : 257-265, 2012.
PubMed
10) Moskovitz DN, et al : The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 99 : 656-661, 2004.
PubMed
11) Coelho J, et al : Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines : cohort from the CESAME Study. Gut 60 : 198-203, 2011.
PubMed
12) Mottet C, et al : Appropriate management of special situations in Crohn's disease (upper gastro-intestinal ; extra-intestinal manifestations ; drug safety during pregnancy and breastfeeding) : Results of a multidisciplinary international expert panel-EPACT II. J Crohns Colitis 3 : 257-263, 2009.
 
P.387 掲載の参考文献
1) 大腸癌研究会 : 大腸癌取扱い規約, 第7版補訂版. 金原出版, 2009.
 
2) Snover DC, et al : Serrated polyps of the colon and rectum and serrated polyposis. In : Bosman FT, et al (eds). WHO Classification of Tumours of the Digestive System, 4th edition, IARC Press, Lyon, France, pp160-165, 2010.
 
3) 山地裕, 他 : 二次スクリーニング法発見大腸癌の特徴 便潜血検査陽性癌と陰性癌の特徴. 早期大腸癌 5, 149-156, 2001.
 
4) Jack S. Mandel, et al : Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328 : 1365-1371, 1993.
 
5) Enrique Quintero, et al : Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 366 : 697-706, 2012.
PubMed
6) 岡志郎, 他 : 早期大腸癌の肉眼分類 側方発育型腫瘍 (LST) とは. 胃と腸 45 : 619-623, 2010.
 
7) Lieberman D, et al : Polyp size and advanced histology in patients undergoing colonoscopy screening : implications for CT colonography. Gastroenterology 135 : 1100-1105, 2008.
PubMed
P.402 掲載の参考文献
1) Mizoue T, et al : Alcohol drinking and colorectal cancer in Japanese : a pooled analysis of results from five cohort studies. Am J Epidemiol 167 : 1397-1406, 2008.
PubMed
2) 大腸癌研究会編 : 大腸癌治療ガイドライン医師用2010年版. 金原出版, 2010.
 
3) Morikawa T, et al : A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 129 : 422-428, 2005.
PubMed
4) National Institute of Health Consensus Conference : Adjuvant therapy for patients with colon and rectal cancer. JAMA 264 : 1444-1450, 1990.
 
5) Benson AB 3rd, et al : American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004 ; 22 : 3408-3419.
 
6) Scheithauer, et al : Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306 : 752-755, 1993.
 
7) Simmons PC : Palliative chemotherapy for advanced colorectal cancer : systematic review and meta-analysis. Colorectal Cancer Collaborative Group.Br Med J 321 : 531-535, 2000.
 
8) Cunningham D, et al : Randomised trial of rinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 : 1413-1418, 1998.
 
P.407 掲載の参考文献
1) Douglas DA : The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology 130 : 1377-1390, 2006.
 
2) Miwa H : Prevalence of irritable bowel syndrome in Japan : Internet survey using Rome III criteria. Patient Prefer Adherence 2 : 143-147, 2008.
PubMed
3) Longstreth GF, et al : Functional bowel disorders. Gastroenterology 130 : 1480-1491, 2006.
PubMed
4) Tillisch K, et al : Advances in imaging the brain-gut axis : functional gastrointestinal disorders. Gastroenterology 140 : 407-411, 2011.
PubMed
5) Barbara G, et al : Postinfectious irritable bowel syndrome. J Pediatr Gastroenterol Nutr. 48 Suppl 2 : S95-97, 2009.
 
6) 福土審, 他 : 過敏性腸症候群. 心身症 診断・治療ガイドライン2006. 11-40, 協和企画, 2006.
 
7) American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, et al : An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 104 Suppl 1 : S1-35, 2009.
 
8) Matsueda K, et al : A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 43 : 1202-1211, 2008.
PubMed
9) Pimentel M, et al : Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364 : 22-32, 2011.
PubMed
10) Furuno T, et al : The spermatogenic Ig superfamily/synaptic cell adhesion molecule mast-cell adhesion molecule promotes interaction with nerves. J Immunol 174 : 6934-6942, 2005.
PubMed
11) Klooker TK, et al : The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 59 : 1213-1221, 2010.
PubMed
P.411 掲載の参考文献
1) Marston A, et al : Ischaemic colitis. Gut 7 : 1-15, 1966.
PubMed
2) Higgins PD, et al : Systematic review : the epidemiology of ischaemic colitis. Aliment Pharmacol Ther 19 : 729-738, 2004.
 
3) Brandt LJ, et al : AGA technical review on intestinal ischemia. American Gastrointestinal Association. Gastroenterology 118 : 954-968, 2000.
PubMed
4) Brandt LJ, et al : Anatomic patterns, patient characteristics, and clinical outcomes in ischemic colitis : a study of 313 cases supported by histology. Am J Gastroenterol 105 : 2245-2252 ; quiz 2253, 2010.
PubMed
5) Huguier M, et al : Ischemic colitis. Am J Surg 192 : 679-684, 2006.
PubMed
P.416 掲載の参考文献
1) Sumi A, et al : Proportion of sporadic gastroenteritis cases caused by rotavirus, norovirus, adenovirus and bacteria in Japan from January 2000 to December 2003. Microbiol Immunol 49 : 745-756, 2005.
PubMed
2) Guerrant RL, et al : Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 32 : 331-351, 2001.
PubMed
3) Barbut F, et al : Comparative value of colonic biopsy and intraluminal fluid culture for diagnosis of bacterial acute colitis in immunocompetent patients. Infectious Colitis Study Group.Clin Infect Dis 29 : 356-360, 1999.
 
4) Shen B, et al : The role of endoscopy in the management of patients with diarrhea. Gastrointest Endosc 71 : 887-892, 2010.
PubMed
5) Santosham M, et al : Oral rehydration therapy for diarrhea : an example of reverse transfer of technology. Pediatrics 100 : E10, 1997.
PubMed
6) Sirinavin S, et al : Antibiotics for treating salmonella gut infections. Cochrane Database Syst Rev, 2000. CD001167.
PubMed
7) Tarr PI, et al : Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365 : 1073-1086, 2005.
PubMed
8) Bell BP, et al : Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157 : H7 infections. Pediatrics 100 : E12, 1997.
PubMed
9) Wong CS, et al : Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157 : H7 : a multivariable analysis. Clin Infect Dis 55 : 33-41, 2012.
PubMed
P.423 掲載の参考文献
1) Miura S, et al : Bilateral type diverticular disease of the colon. Int J Colorectal Dis 11 : 71-75, 1996.
PubMed
2) 井上幹夫 : 大腸憩室疾患の疫学と臨床. 日本大腸肛門病学会雑誌 45 : 904-913, 1992.
 
3) Schwerk WB, et al : Sonography in acute colonic diverticulitis. A prospective study. Dis Colon Rectum 35 : 1077-1084, 1992.
PubMed
4) Rafferty J, et al : Practice parameters for sigmoid diverticulitis. Dis Colon Rectum 49 : 939-944, 2006.
PubMed
5) Chapman JR, et al : Diverticulitis : a progressive disease? Do multiple recurrences predict less favorable outcomes? Ann Surg 243 : 876-830 ; discussion 880-883, 2006.
 
6) 宮城良充 : 【消化器救急疾患とその対応】虫垂炎. 外科治療 93 : 678-688, 2005.
 
7) 笹壁弘嗣 : 【腹痛診断へのアプローチ】急性虫垂炎へのアプローチ. 治療 90 : 2529-2533, 2008.
 
8) Vons C, et al : Amoxicillin plus clavulanic acid versus appendicectomy for treatment of acute uncomplicated appendicitis : an open-label, non-inferiority, randomised controlled trial. Lancet 377 : 1573-1579, 2011.
PubMed
9) Deans GT, et al : Neoplastic lesions of the appendix. Br J Surg 82 : 299-306, 1995.
PubMed
P.426 掲載の参考文献
1) Ali S, et al : Pharmacological interventions for the prevention and treatment of radiation colitis, enteritis and proctitis. Cochrane Database of Systematic Reviews 2011, Issue 2. Art. No. : CD008971.
 
2) Sherman LF : A reevaluation of the factitial proctitis problem. Am J Surg 88 : 773-779, 1954.
PubMed
3) 多田正大, 他 : 内視鏡的色素散布法による放射線性直腸炎についての研究. 日消誌 74 : 441-448, 1977.
 
4) Andreyev HJ, et al : Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut 61 : 179-192, 2012.
PubMed
5) 千野晶子, 他 : 放射線性腸炎の対処法. 消化器内視鏡 23 : 1997-2004, 2011.
Medical*Online
P.430 掲載の参考文献
1) WHO classification of tumours of the digestive systems Eds : Bosman FT et al. 4th ed, 2010.
 
2) Rindi G, et al : Three subtypes of gastric argyrophil carcinoids and the gastric neuroendocrine carcinoma : A clinicopathological study. Gastroenterology 104 : 994-1006, 1993.
PubMed
3) Tichansky DS, et al : Risk of second cancers in patients with colorectal carcinoids. Dis Colon Rectum 45 : 91-97, 2002.
PubMed
4) Gianfranco DF, et al : ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 95 : 74-87, 2012.
 
5) Martyn C, et al : ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms : Colorectal neuroendocrine neoplasms. Neuroendocrinology 95 : 88-97, 2012.
 
6) Modlin IM, et al : Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 4 : 526-547, 2006.
PubMed
7) Oberg K, et al : Consensus report on the use of somatostation analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15 : 966-973, 2004.
 
8) Rinke A, et al : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group.J Clin Oncol 27 : 4656-4663, 2009.
 

附) 症候

P.439 掲載の参考文献
1) 金澤一郎, 他 : 内科学. 第1版, p.147-151, 医学書院, 2006.
 
2) 小川聡, 他 : 内科学書. 第7版, p.250-252, 中山書店, 2009.
 
3) 日本臨床内科医会 : 内科診療実践マニュアル. p.324-326, 日本医学出版, 2009.
 
4) 福井次矢, 他 : ハリソン内科学. 第3版, p.97-99, メディカル・サイエンス・インターナショナル, 2009.
 
P.444 掲載の参考文献
1) 日本消化器内視鏡学会 : 消化器内視鏡ガイドライン, 第3版, 2006.
 
2) 熊井浩一郎 : 消化管出血に対する内視鏡的止血の進歩 ; 最新消化器内視鏡治療, 先端医療技術研究所
 
3) Barkun AN, et al : International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 152 : 101-113, 2010.
PubMed
4) Strate LL. Lower GI bleeding : epidemiology and diagnosis. Gastroenterol Clin North Am 34 : 643-664, 2005.
PubMed
5) Jensen DM, et al : Urgent colonoscopy for the diagnosis and treatment of severe diverticular hemorrhage. N Engl J Med 342 : 78-82, 2000.
PubMed
6) Cohn SM, et al : Angiography for preoperative evaluation in patients with lower gastrointestinal bleeding : are the benefits worth the risks? Arch Surg 133 : 50-55, 1998.
PubMed
P.454 掲載の参考文献
1) Twycross R : Palliative care. The joy of death. Lancet 350 : SIII20, 1997.
PubMed
2) Caraceni A : An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 82 : 263-274, 1999.
 
3) 日本緩和医療学会 : がん疼痛の薬物療法に関するガイドライン, 2010.
 

書評

最近チェックした商品履歴

Loading...